NCT00365443WithdrawnPhase 2
Proprietary Information - Exploratory (Non-Confirmatory) Trial
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Merck Sharp & Dohme LLC
- Primary Endpoint
- Proprietary Information - Exploratory (Non-Confirmatory) Trial
Study Overview
Brief Summary
This study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection caused by the HPV types in the study vaccine, (2) To demonstrate that the vaccine is well-tolerated in women, (3) To evaluate vaccine immune responses in women.
This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Double
Eligibility Criteria
- Ages
- 16 Years to 26 Years (Child, Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Female, between the ages of 16 and 26
Exclusion Criteria
- •History of an abnormal PAP test or abnormal cervical biopsy result
- •History of external genital/vaginal warts
- •History of positive HPV test
- •Currently a user of any illegal drugs or an alcohol abuser
- •Are pregnant
- •Currently enrolled in another clinical trial
- •Currently has or has a history of certain medical conditions or is currently taking or has taken certain medications (details will be discussed at the time of consent).
Outcomes
Primary Outcomes
Proprietary Information - Exploratory (Non-Confirmatory) Trial
Secondary Outcomes
- Proprietary Information - Exploratory (Non-Confirmatory) Trial
Investigators
Similar Trials
Withdrawn
Phase 1
TG4040 in Patients With Chronic HCVHepatitis CNCT00449124National Institute of Allergy and Infectious Diseases (NIAID)
Completed
Phase 1
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of InfluenzaInfluenza, HumanNCT05227001Pfizer440
Completed
Phase 2
Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine CandidateInfluenzaNCT00363077GlaxoSmithKline150
Unknown
Phase 1
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in AdultsCovid19NCT04798001Meissa Vaccines, Inc.130
Completed
Phase 1
A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of AgeRESPIRATORY SYNCYTIAL VIRUS (RSV)NCT05900154Pfizer128